{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:55:28Z","timestamp":1793332528300,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"publisher","award":["MTA-BCE PPD 462025"],"award-info":[{"award-number":["MTA-BCE PPD 462025"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006419","name":"EuroQol Research Foundation","doi-asserted-by":"publisher","award":["20170500"],"award-info":[{"award-number":["20170500"]}],"id":[{"id":"10.13039\/501100006419","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jval.2020.03.019","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T08:27:35Z","timestamp":1597220855000},"page":"1235-1245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary"],"prefix":"10.1016","volume":"23","author":[{"given":"Fanni","family":"Rencz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Brodszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Gul\u00e1csi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Golicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Ruzsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Simon","family":"Pickard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest H.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rta","family":"P\u00e9ntek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.jval.2020.03.019_bib1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1017\/S0266462309090527","article-title":"History of health technology assessment in Hungary","volume":"25","author":"Gulacsi","year":"2009","journal-title":"Int J Technol Assess Health Care"},{"issue":"suppl 1","key":"10.1016\/j.jval.2020.03.019_bib2","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/s10198-014-0590-8","article-title":"Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria","volume":"15","author":"Gulacsi","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2020.03.019_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10198-007-0046-5","article-title":"The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience","volume":"8","author":"Gulacsi","year":"2007","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2020.03.019_bib4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(06)69369-0","article-title":"Financial deficits in the health services of the UK and Hungary","volume":"368","author":"Boncz","year":"2006","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jval.2020.03.019_bib6","first-page":"821","article-title":"Az Emberi Er\u0151forr\u00e1sok Miniszt\u00e9riuma szakmai ir\u00e1nyelve az eg\u00e9szs\u00e9g\u00fcgyi technol\u00f3gia \u00e9rt\u00e9kel\u00e9s m\u00f3dszertan\u00e1r\u00f3l \u00e9s ennek keret\u00e9ben k\u00f6lts\u00e9ghat\u00e9konys\u00e1gi elemz\u00e9sek k\u00e9sz\u00edt\u00e9s\u00e9r\u0151l","volume":"3","year":"2017","journal-title":"Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zl\u00f6ny"},{"key":"10.1016\/j.jval.2020.03.019_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40273-017-0544-y","article-title":"International regulations and recommendations for utility data for health technology assessment","volume":"35","author":"Rowen","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.03.019_bib8","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s11136-016-1375-6","article-title":"EQ-5D in Central and Eastern Europe: 2000-2015","volume":"25","author":"Rencz","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2020.03.019_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","article-title":"EQ-5D and the EuroQol Group: past, present and future","volume":"15","author":"Devlin","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"10.1016\/j.jval.2020.03.019_bib10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/0272989X19841587","article-title":"Cultural values: can they explain differences in health utilities between countries?","volume":"39","author":"Roudijk","year":"2019","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2020.03.019_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol \u2013 a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.jval.2020.03.019_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"10.1016\/j.jval.2020.03.019_bib13","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2020.03.019_bib14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40273-018-0628-3","article-title":"Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets","volume":"36","author":"Mulhern","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.03.019_bib15","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/0272989X18802797","article-title":"Parallel valuation: a direct comparison of EQ-5D-3L and EQ-5D-5L societal value sets","volume":"38","author":"Law","year":"2018","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2020.03.019_bib16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40273-018-0647-0","article-title":"Head-to-head comparison of EQ-5D-3L and EQ-5D-5L health values","volume":"36","author":"Selivanova","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.03.019_bib17","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s11136-014-0897-z","article-title":"Do health preferences contradict ordering of EQ-5D labels?","volume":"24","author":"Craig","year":"2015","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2020.03.019_bib18","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jval.2018.05.002","article-title":"Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) health states:\u00a0the impact of wording and perspective","volume":"21","author":"Kreimeier","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.03.019_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/0272989X13480852","article-title":"Comparing EQ-5D valuation studies: a systematic review and methodological reporting checklist","volume":"34","author":"Xie","year":"2014","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2020.03.019_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jval.2018.05.010","article-title":"Overview, update, and lessons learned from the international EQ-5D-5L Valuation Work:\u00a0version 2 of the EQ-5D-5L Valuation Protocol","volume":"22","author":"Stolk","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.03.019_bib21","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","article-title":"United States valuation of EQ-5D-5L\u00a0Health\u00a0States using an international protocol","volume":"22","author":"Pickard","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.03.019_bib22","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1007\/s11136-019-02249-y","article-title":"A\u00a0comparison of self-rated health using EQ-5D VAS in the United States in 2002 and 2017","volume":"28","author":"Cha","year":"2019","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2020.03.019_bib23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jval.2014.04.002","article-title":"A\u00a0program of methodological research to arrive at the new international EQ-5D-5L valuation protocol","volume":"17","author":"Oppe","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.03.019_bib25","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jval.2016.10.012","article-title":"Quality control process for EQ-5D-5L valuation studies","volume":"20","author":"Ramos-Goni","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.03.019_bib26","author":"Oppe"},{"issue":"suppl 1","key":"10.1016\/j.jval.2020.03.019_bib27","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s10198-013-0503-2","article-title":"Introducing the composite time trade-off: a test of feasibility and face validity","volume":"14","author":"Janssen","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2020.03.019_bib28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","article-title":"German value set for the EQ-5D-5L","volume":"36","author":"Ludwig","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.03.019_bib29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s40273-018-0690-x","article-title":"Utility values for health states in Ireland: a value set for the EQ-5D-5L","volume":"36","author":"Hobbins","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.03.019_bib30","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40273-017-0538-9","article-title":"The Indonesian EQ-5D-5L value set","volume":"35","author":"Purba","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.03.019_bib31","first-page":"173","article-title":"Heteroscedastic censored and truncated regression with crch","volume":"8","author":"Messner","year":"2016","journal-title":"R\u00a0J"},{"key":"10.1016\/j.jval.2020.03.019_bib32","author":"Berger"},{"key":"10.1016\/j.jval.2020.03.019_bib33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.03.019_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/hec.3560","article-title":"New methods for modelling EQ-5D-5L value sets: an application to English data","volume":"27","author":"Feng","year":"2018","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2020.03.019_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2020.03.019_bib36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MLR.0b013e3181c162a2","article-title":"Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments","volume":"48","author":"Luo","year":"2010","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2020.03.019_bib37","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jval.2016.11.015","article-title":"Instrument-defined estimates of the minimally important difference for EQ-5D-5L Index scores","volume":"20","author":"McClure","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.03.019_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"key":"10.1016\/j.jval.2020.03.019_bib39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1524-4733.2009.00596.x","article-title":"Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe","volume":"13","author":"Golicki","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.03.019_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vhri.2014.06.001","article-title":"Interim EQ-5D-5L value set for Poland: first crosswalk value set in Central and Eastern Europe","volume":"4","author":"Golicki","year":"2014","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jval.2020.03.019_bib41","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s40273-019-00811-7","article-title":"Valuation of EQ-5D-5L health states in Poland: the first EQ-VT-based study in Central and Eastern Europe","volume":"37","author":"Golicki","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.03.019_bib42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2478\/sjph-2020-0002","article-title":"Valuation of EQ-5D-3L health states in Slovenia: VAS based and TTO based value sets","volume":"59","author":"Prevolnik Rupel","year":"2019","journal-title":"Slovenian J Public Health"},{"key":"10.1016\/j.jval.2020.03.019_bib43","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40273-018-0642-5","article-title":"A\u00a0systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D","volume":"36","author":"Buchholz","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.03.019_bib44","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","article-title":"Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study","volume":"22","author":"Janssen","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2020.03.019_bib45","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40273-018-0623-8","article-title":"Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries","volume":"36","author":"Janssen","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.03.019_bib46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40273-018-0622-9","article-title":"5L, what the L? A NICE conundrum","volume":"36","author":"Devlin","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.03.019_bib47","unstructured":"Mullett TL, McDonald R, Tsuchiya A. Understanding the composite dimensions of the EQ-5D: an experimental approach. Presented at: EuroQol 35th Plenary Meeting; September 19-21, 2018; Lisbon, Portugal."},{"key":"10.1016\/j.jval.2020.03.019_bib48","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00296-017-3800-8","article-title":"EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis","volume":"37","author":"Zrubka","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jval.2020.03.019_bib49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10198-019-01069-8","article-title":"A\u00a0comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases","volume":"20","author":"Zrubka","year":"2019","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2020.03.019_bib50","doi-asserted-by":"crossref","first-page":"860","DOI":"10.5603\/KP.a2018.0033","article-title":"EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature","volume":"76","author":"Batog","year":"2018","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.jval.2020.03.019_bib51","series-title":"2014-ben v\u00e9grehajtott Eur\u00f3pai lakoss\u00e1gi eg\u00e9szs\u00e9gfelm\u00e9r\u00e9s (ELEF) eredm\u00e9nyei","author":"KSH","year":"2018"},{"key":"10.1016\/j.jval.2020.03.019_bib52","first-page":"1667","article-title":"Health-related quality of life of the Hungarian population","volume":"144","author":"Szende","year":"2003","journal-title":"Orv Hetil"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520321173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520321173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:59:33Z","timestamp":1778590773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520321173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1098301520321173"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.03.019","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}